Breast Cancer Stage II, Breast Cancer Stage III, Solid Tumor
Conditions
Brief summary
This is a single arm study to determining the value of apoptotic molecular probe SF-DEVD-2 in the early evaluation of tumor efficacy and comparing it head-to-head wihe 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose)
Interventions
DRUG[18F]SF-DEVD-2
Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2
DRUG[18F]-FDG
Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG
Sponsors
Affiliated Hospital of Jiangnan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients voluntarily signed informed consent; 2. Age18-70, male or female; 3. Diagnosed with stage 2 or 3 breast cancer 4. Solid tumors、masses larger than 2cm with lymph node metastasis 5. Pathology is HER3+、triple negative patients 6. Patients to be treated with neoadjuvant chemotherapy
Exclusion criteria
1. Age greater than or equal to 70 years old 2. Abnormal liver and kidney function (more than five times the normal value) 3. Diagnosis level of breast cancer stage 4 or second time tumor patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of tissue distribution of [18F]-DEVD-2 | 7 days | Biodistribution of \[18F\] -DEVD-2 evaluated by the maximum standardized uptake value（SUVmax) in various organs during repeated \[18F\]-DEVD scans will be reported. |
Countries
China
Contacts
Primary ContactChunjing Yu
Outcome results
None listed